Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
Active, not recruiting · Phase 2 · NCT01880567
Conditions: CCND1 Positive, CCND2 Positive, CCND3 Positive, CD20 Positive, Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
At a glance
- Research payments reported, 2025
- $846,636
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 113
About the trial
- Sponsor
- M.D. Anderson Cancer Center (with National Cancer Institute (NCI))
- Tested
- Ibrutinib (drug), Laboratory Biomarker Analysis (other), Rituximab (biological)
- Dates
- Started 2013-07-15; completion 2028-07-31
- Results posted
- Not yet
This phase II trial studies how well ibrutinib and rituximab work in treating patients with mantle cell lymphoma that has come back or has not responded to treatment or older patients with newly diagnosed mantle cell lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them. Giving ibrutinib and rituximab may be an effective treatment for mantle cell lymphoma.
From ClinicalTrials.gov, last updated 2026-07-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $846,636 in research payments for this study in 2025 (1 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $846,636
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.